全文获取类型
收费全文 | 7762篇 |
免费 | 437篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 137篇 |
儿科学 | 255篇 |
妇产科学 | 131篇 |
基础医学 | 1004篇 |
口腔科学 | 193篇 |
临床医学 | 592篇 |
内科学 | 2104篇 |
皮肤病学 | 90篇 |
神经病学 | 877篇 |
特种医学 | 328篇 |
外科学 | 1028篇 |
综合类 | 37篇 |
一般理论 | 8篇 |
预防医学 | 456篇 |
眼科学 | 150篇 |
药学 | 397篇 |
中国医学 | 14篇 |
肿瘤学 | 438篇 |
出版年
2024年 | 12篇 |
2023年 | 71篇 |
2022年 | 216篇 |
2021年 | 363篇 |
2020年 | 211篇 |
2019年 | 283篇 |
2018年 | 343篇 |
2017年 | 233篇 |
2016年 | 233篇 |
2015年 | 287篇 |
2014年 | 357篇 |
2013年 | 415篇 |
2012年 | 654篇 |
2011年 | 670篇 |
2010年 | 347篇 |
2009年 | 289篇 |
2008年 | 529篇 |
2007年 | 454篇 |
2006年 | 394篇 |
2005年 | 434篇 |
2004年 | 380篇 |
2003年 | 282篇 |
2002年 | 250篇 |
2001年 | 72篇 |
2000年 | 61篇 |
1999年 | 55篇 |
1998年 | 44篇 |
1997年 | 43篇 |
1996年 | 29篇 |
1995年 | 26篇 |
1994年 | 22篇 |
1993年 | 15篇 |
1992年 | 26篇 |
1991年 | 20篇 |
1990年 | 9篇 |
1989年 | 13篇 |
1988年 | 12篇 |
1987年 | 13篇 |
1986年 | 10篇 |
1985年 | 11篇 |
1984年 | 6篇 |
1983年 | 6篇 |
1982年 | 6篇 |
1981年 | 8篇 |
1980年 | 4篇 |
1977年 | 3篇 |
1972年 | 2篇 |
1971年 | 2篇 |
1969年 | 2篇 |
1968年 | 2篇 |
排序方式: 共有8239条查询结果,搜索用时 15 毫秒
51.
52.
de Diego Rodríguez E del Valle Schaan JI Gutiérrez Baños JL Martín García B Hernández Rodríguez R Portillo Martín JA Correas Gómez MA Roca Edreira A Villanueva Peña A Rado Velázquez MA Hernández Rodríguez A 《Actas urologicas espa?olas》2000,24(10):836-839
Prostatic carcinoma may be diagnosed by the clinic manifestations or by the symptoms for locoregional disemination and distance metastasis. The lymphatic system is the first metastatic station, which is affected in a high percentage of cases. Event it may simulate lymphoproliferatives process and it si uncommon the lymphatic macroaffectation at first. In theses cases, the histologic and immunohistochemical study by the determination of prostatic specific antigen in lymph nodes can provice the diagnosis. Treatment of these tumors is palliative with hormonotherapy. Prognosis is bad with a low survival at five years. 相似文献
53.
The potential use of genetic tests in insurance has raised concerns about discrimination and individuals losing access to health care either because of refusals to test for treatable diseases, or because test-positives cannot afford premiums. Governments have so far largely sought to restrict the use of genetic information by insurance companies. To date the number of tests available with significant actuarial value is limited. However, this is likely to change, raising more clearly the question as to whether the social costs of adverse selection outweigh the social costs of individuals not accessing health care for fear of the consequences of test information being used in insurance markets. In this contribution we set out the policy context and model the potential trade-offs between the losses faced by insurers from adverse selection by insurees (which will increase premiums reducing consumer welfare) and the detrimental health effects that may result from persons refusing to undergo tests that could identify treatable health conditions. It argues that the optimal public policy on genetic testing should reflect overall societal benefit, taking account of these trade-offs. Based on our model, the factors that influence the outcome include: the size of and value attached to the health gains from treatment; deterrent effects of a disclosure requirement on testing for health reasons; incidence of the disease; propensity of test-positives to adverse select; policy value adverse selectors buy in a non-disclosure environment; and price elasticity of demand for insurance. Our illustrative model can be used as a benchmark for developing other scenarios or incorporating real data in order to address the impact of different policies on disclosure and requirement to test. 相似文献
54.
Fabio Scopesi Silvana Canini Cesare Arioni Massimo Mazzella Diego Gazzolo Pasquale B Lantieri Wanda Bonacci Giovanni Serra 《The journal of maternal-fetal & neonatal medicine》2006,19(6):343-346
BACKGROUND: Recently we demonstrated an increased 2,3-diphosphoglycerate (2,3-DPG) erythrocyte concentration in rat pups subjected to nucleotide-enriched artificial feeding. DESIGN: The present study was carried out to test the hypothesis that a possible increase in 2,3-DPG concentration can also be obtained in human neonates who are fed nucleotide-enriched formula. Preterm neonates born or referred to the neonatal intensive care unit of the G. Gaslini Hospital, Genoa University, with a gestational age >30 weeks and <37 weeks were enrolled in our randomized trial. Recruitment took place within 48-72 hours from birth. Only newborns of mothers deciding not to breast-feed were eligible to be randomized for the supplemented group (FN) or non-supplemented group (RF). Breast-fed newborns were considered the control group (C). The study window (for supplementation and blood samples) was restricted to the first two weeks following birth (from the 2nd (t1) to the 16th (t2) day of life). At the end of our study, only 21 neonates were eligible for statistical analysis. RESULTS: The stimulating action of dietary nucleotides on 2,3-DPG concentration failed to be demonstrated; increases in 2,3-DPG concentration that were observed in newborns fed with nucleotide supplemented formula (FN) were comparable to those observed in newborns fed with regular formula (RF) and breast-fed newborns. CONCLUSIONS: The EC recommendation for the amount of nucleotides allowed in formula milk does not seem to be high enough to have positive effects on 2,3-DPG synthesis. Whether this possible 'pharmacological' effect can be achieved by a higher intake of ingested nucleotides and/or a change in the proportions of single nucleotides contained in milk formulas remain interesting end points to be elucidated. 相似文献
55.
56.
Mother milk is widely accepted to be a unique product believed to contain biological factors involved in the regulation of newborn optimal growth including brain when compared to milk-formula milks. In this setting, there is growing evidence that in milk-formula neuro-oxidative stress biomarkers, neurotrophic proteins and calcium binding proteins, known to be involved in a cascade of events leading to brain, cardiac and vascular development/damage, are to date lacking or at a lower concentration than breast milk. Therefore, this review is aimed at offering additional insights to the role in human milk of some selected biomarkers such as: i) neurotrophic factors such as Activin A; ii) Calcium binding protein such as S100B and, iii) heat shock protein known to be involved in oxidative stress response (namely hemeoxygenase-1, HO-1 or Heat shock Protein 32, HSP32). 相似文献
57.
Grainne Holleran Franco Scaldaferri Antonio Gasbarrini Diego Curr 《Phytotherapy research : PTR》2020,34(1):77-93
Inflammatory bowel disease patients frequently use herbal products as complementary or alternative medicines to current pharmacotherapies and obtain information on them mainly from the internet, social media, or unlicensed practitioners. Clinicians should therefore take a more active role and become knowledgeable of the mechanisms of action and potential drug interactions of herbal medicines for which evidence of efficacy is available. The therapeutic efficacy and safety of several herbal medicines have been studied in double‐blind randomised controlled trials (RCTs). Evidence of efficacy is available for Andrographis paniculata extract; curcumin; a combination of myrrh, extract of chamomile flower, and coffee charcoal; and the Chinese herbal medicines Fufangkushen colon‐coated capsule and Xilei san in patients with ulcerative colitis; and Artemisia absinthium extract and Boswellia serrata resin extract in patients with Crohn's disease. However, most of this evidence comes from single small RCTs with short follow‐up, and the long‐term effects and safety of their use have not yet been established. Thus, our findings indicate that further appropriately sized RCTs are necessary prior to the recommended use of these herbal medicines in therapy. In the meantime, increasing awareness of their use, and potential drug interactions among physicians may help to reduce unwanted effects and adverse disease outcomes. 相似文献
58.
59.
Zanardo V Vedovato S Chiozza L Faggian D Favaro F Trevisanuto D 《American journal of perinatology》2008,25(6):353-358
Widened pulse pressure is a classic sign of significant left-to-right shunting patent ductus arteriosus (PDA), but little evidence supports this statement in the early life of premature infants with respiratory distress syndrome (RDS) needing nonsteroidal anti-inflammatory drugs (NSAIDs), the pharmacological treatment for PDA. Pulse pressure and urinary endothelin-1 (ET-1) and arginine vasopressin (AVP) vasoactive factors involved in the transitional circulation were measured before and after the NSAIDs treatment of 46 RDS premature infants receiving either ibuprofen (n = 22) or indomethacin (n = 24), with 28 responders and 18 nonresponders to the first NSAIDs course. We found that following pharmacological PDA closure, systolic and diastolic blood pressure significantly increased, maintaining a stable pulse pressure. However, when pharmacological closure failed, the trend (nonsignificant) was for a more consistent increase in systolic than in diastolic blood pressure, which determined a statistically significant widening pulse pressure. In addition, urinary ET-1 excretion rates decreased significantly after PDA closure, whereas persistent more aggressive pharmacological therapy failed. Urinary AVP excretion rates decreased insignificantly after therapy, uninfluenced by the efficacy of the drugs. We concluded that widened pulse pressure is a clinical sign of failed PDA pharmacological closure in RDS premature infants. ET-1 levels remain elevated when NSAIDs fail to interrupt left-to-right PDA shunting that complicates recovery from RDS. 相似文献
60.
Valentina Hernndez Davor Ibarra Johan F. Triana Bastian Martínez-Soto Matías Faúndez Diego A. Vasco Leonardo Gordillo Felipe Herrera Claudio García-Herrera Alysia Garmulewicz 《Materials》2022,15(11)
This article focuses on agar biopolymer films that offer promise for developing biodegradable packaging, an important solution for reducing plastics pollution. At present there is a lack of data on the mechanical performance of agar biopolymer films using a simple plasticizer. This study takes a Design of Experiments approach to analyze how agar-glycerin biopolymer films perform across a range of ingredients concentrations in terms of their strength, elasticity, and ductility. Our results demonstrate that by systematically varying the quantity of agar and glycerin, tensile properties can be achieved that are comparable to agar-based materials with more complex formulations. Not only does our study significantly broaden the amount of data available on the range of mechanical performance that can be achieved with simple agar biopolymer films, but the data can also be used to guide further optimization efforts that start with a basic formulation that performs well on certain property dimensions. We also find that select formulations have similar tensile properties to thermoplastic starch (TPS), acrylonitrile butadiene styrene (ABS), and polypropylene (PP), indicating potential suitability for select packaging applications. We use our experimental dataset to train a neural network regression model that predicts the Young’s modulus, ultimate tensile strength, and elongation at break of agar biopolymer films given their composition. Our findings support the development of further data-driven design and fabrication workflows. 相似文献